Skip to Main Navigation
Skip to Page Content
Share This:
https://ntp.niehs.nih.gov/go/5710

TDMS Study 56111-04 Pathology Tables

NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01
Route: DOSED FEED                                                                                                 Time: 09:19:23

                                                          Final#1/Mice




       Facility:  Battelle Columbus Laboratory

       Chemical CAS #:  14371-10-9

       Lock Date:  06/28/00

       Cage Range:  All

       Reasons For Removal:    All

       Removal Date Range:     All

       Treatment Groups:       Include All


































a  Number of animals examined microscopically at site and number of animals with lesion

                                                              Page   1


NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50           50                        
  Early Deaths                                                                                                                      
    Natural Death                                      5            6            9            5            3                        
    Moribund Sacrifice                                 2            3            4            1            4                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                42           41           36           44           43                        
    Natural Death                                      1                         1                                                  
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50           50                        
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Gallbladder                                        (50)         (50)         (50)         (50)         (50)                      
   Intestine Large, Colon                             (50)         (50)         (50)         (50)         (50)                      
   Intestine Large, Rectum                            (50)         (50)         (50)         (50)         (50)                      
      Squamous Cell Carcinoma, Metastatic, Skin                                               1 (2%)                                
   Intestine Large, Cecum                             (50)         (50)         (50)         (49)         (50)                      
   Intestine Small, Duodenum                          (50)         (49)         (50)         (50)         (50)                      
      Polyp Adenomatous                                                          1 (2%)                                             
   Intestine Small, Jejunum                           (50)         (50)         (50)         (50)         (50)                      
      Carcinoma                                                     1 (2%)                                                          
   Liver                                              (50)         (49)         (50)         (50)         (50)                      
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
      Hepatocellular Carcinoma                         1 (2%)       2 (4%)                                                          
      Hepatocellular Adenoma                           4 (8%)       3 (6%)       4 (8%)       2 (4%)       1 (2%)                   
      Histiocytic Sarcoma                                           1 (2%)       1 (2%)       1 (2%)                                
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                                                   1 (2%)                                             
   Mesentery                                          (3)          (4)          (5)          (4)          (1)                       
      Carcinoma, Metastatic, Uterus                                                           1 (25%)                               
      Fibrosarcoma                                     1 (33%)                                                                      
      Hemangioma                                       1 (33%)                                                                      
      Histiocytic Sarcoma                                                        1 (20%)      1 (25%)                               
      Rhabdomyosarcoma, Metastatic, Skeletal Muscle    1 (33%)                                                                      
   Pancreas                                           (50)         (50)         (50)         (50)         (50)                      
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Salivary Glands                                    (48)         (50)         (48)         (49)         (50)                      
   Stomach, Forestomach                               (50)         (50)         (50)         (50)         (50)                      
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Squamous Cell Carcinoma                                                                 1 (2%)                                
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   2                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
ALIMENTARY SYSTEM - cont                                                                                                            
      Squamous Cell Papilloma                          1 (2%)                                 3 (6%)                                
   Tooth                                                           (2)                       (1)          (1)                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (49)         (50)         (50)         (50)         (50)                      
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                                  1 (2%)                                             
      Hemangioma                                                                 1 (2%)                                             
      Histiocytic Sarcoma                                           1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (50)         (50)         (50)         (50)         (50)                      
      Subcapsular, Adenoma                                                                                 1 (2%)                   
   Adrenal Medulla                                    (49)         (50)         (50)         (50)         (50)                      
      Pheochromocytoma Malignant                                    1 (2%)                                                          
      Pheochromocytoma Benign                                                                 1 (2%)       1 (2%)                   
   Pituitary Gland                                    (48)         (49)         (50)         (49)         (50)                      
      Pars Distalis, Adenoma                           5 (10%)      6 (12%)      1 (2%)       4 (8%)       2 (4%)                   
      Pars Intermedia, Adenoma                                                                1 (2%)                                
   Thyroid Gland                                      (48)         (50)         (49)         (50)         (50)                      
      Follicular Cell, Adenoma                                      1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   Tissue NOS                                                                                (1)                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Clitoral Gland                                     (50)         (49)         (50)         (49)         (50)                      
      Carcinoma                                                     1 (2%)                                                          
   Ovary                                              (50)         (50)         (50)         (49)         (50)                      
      Cystadenoma                                      2 (4%)                    2 (4%)       1 (2%)       1 (2%)                   
      Granulosa Cell Tumor Benign                                   1 (2%)                                 1 (2%)                   
      Hemangioma                                       1 (2%)                                                                       
      Hemangiosarcoma                                               1 (2%)                    1 (2%)       1 (2%)                   
      Luteoma                                          1 (2%)       1 (2%)       1 (2%)                    1 (2%)                   
      Thecoma Benign                                                1 (2%)                                                          
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   3                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
GENITAL SYSTEM - cont                                                                                                               
   Oviduct                                            (1)          (1)          (2)          (3)          (4)                       
      Histiocytic Sarcoma                                                                     1 (33%)                               
   Uterus                                             (50)         (50)         (50)         (50)         (50)                      
      Carcinoma                                                                               1 (2%)                                
      Hemangioma                                                    1 (2%)                                                          
      Histiocytic Sarcoma                                                        1 (2%)       1 (2%)                                
      Leiomyosarcoma                                                1 (2%)                                                          
      Polyp Stromal                                    1 (2%)                                              1 (2%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (50)         (50)         (50)         (50)                      
      Mast Cell Tumor Malignant                        1 (2%)                                                                       
   Lymph Node                                         (7)          (5)          (7)          (10)         (7)                       
      Lumbar, Histiocytic Sarcoma                                                             1 (10%)                               
      Mediastinal, Alveolar/Bronchiolar Carcinoma,                                                                                  
           Metastatic, Lung                                                      1 (14%)                                            
      Mediastinal, Carcinoma, Metastatic, Uterus                                              1 (10%)                               
      Pancreatic, Histiocytic Sarcoma                                                         1 (10%)                               
      Pancreatic, Osteosarcoma, Metastatic,                                                                                         
          Uncertain Primary Site                                                 1 (14%)                                            
      Pancreatic, Rhabdomyosarcoma, Metastatic,                                                                                     
           Skeletal Muscle                             1 (14%)                                                                      
   Lymph Node, Mandibular                             (46)         (47)         (45)         (49)         (47)                      
      Mast Cell Tumor Malignant                        1 (2%)                                                                       
   Lymph Node, Mesenteric                             (49)         (49)         (50)         (49)         (50)                      
      Carcinoma, Metastatic, Clitoral Gland                         1 (2%)                                                          
      Hemangiosarcoma                                                                         2 (4%)                                
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Spleen                                             (48)         (49)         (50)         (50)         (50)                      
      Hemangiosarcoma                                                                         2 (4%)       1 (2%)                   
   Thymus                                             (46)         (47)         (46)         (47)         (47)                      
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                                  1 (2%)                                             
      Histiocytic Sarcoma                                           1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   4                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Mammary Gland                                      (50)         (50)         (50)         (50)         (50)                      
      Adenoma                                                                                 1 (2%)                                
      Fibroadenoma                                                               1 (2%)                                             
   Skin                                               (50)         (50)         (50)         (50)         (50)                      
      Squamous Cell Carcinoma                          1 (2%)                                 1 (2%)                                
      Subcutaneous Tissue, Fibrosarcoma                2 (4%)       2 (4%)       3 (6%)                                             
      Subcutaneous Tissue, Hemangioma                               1 (2%)                                                          
      Subcutaneous Tissue, Histiocytic Sarcoma                      1 (2%)                    1 (2%)                                
      Subcutaneous Tissue, Schwannoma Malignant        1 (2%)       1 (2%)                                 1 (2%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (50)         (50)         (50)         (50)                      
      Vertebra, Osteosarcoma                                        1 (2%)                                                          
   Skeletal Muscle                                    (1)                                                                           
      Rhabdomyosarcoma                                 1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)         (50)         (50)         (50)                      
      Alveolar/Bronchiolar Adenoma                     1 (2%)       2 (4%)       1 (2%)                                             
      Alveolar/Bronchiolar Carcinoma                   2 (4%)                    2 (4%)       1 (2%)       1 (2%)                   
      Carcinoma, Metastatic, Clitoral Gland                         1 (2%)                                                          
      Carcinoma, Metastatic, Harderian Gland                                     1 (2%)                                             
      Carcinoma, Metastatic, Uncertain Primary Site                 1 (2%)                                                          
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
      Hepatocellular Carcinoma, Metastatic, Liver      1 (2%)                                                                       
      Histiocytic Sarcoma                                           1 (2%)                                                          
      Osteosarcoma, Metastatic, Bone                                1 (2%)                                                          
      Osteosarcoma, Metastatic, Uncertain Primary                                                                                   
          Site                                         1 (2%)                    1 (2%)                                             
      Rhabdomyosarcoma, Metastatic, Skeletal Muscle    1 (2%)                                                                       
      Squamous Cell Carcinoma, Metastatic, Skin                                               1 (2%)                                
   Nose                                               (49)         (50)         (50)         (50)         (50)                      
   Pleura                                             (1)                                                                           
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   5                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
RESPIRATORY SYSTEM - cont                                                                                                           
      Rhabdomyosarcoma, Metastatic, Skeletal Muscle    1 (100%)                                                                     
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (2)          (1)          (4)          (5)                                    
      Adenoma                                          1 (50%)      1 (100%)     3 (75%)      3 (60%)                               
      Carcinoma                                        1 (50%)                   1 (25%)      2 (40%)                               
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (50)         (50)         (50)         (50)                      
      Carcinoma, Metastatic, Uterus                                                           1 (2%)                                
   Urinary Bladder                                    (50)         (50)         (50)         (50)         (50)                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)        *(50)                      
      Histiocytic Sarcoma                                           2 (4%)       1 (2%)       1 (2%)                                
      Lymphoma Malignant                              13 (26%)     10 (20%)      6 (12%)      8 (16%)     14 (28%)                  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   6                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE FEMALE                        UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            32          29          21          24          21                           
     Total Primary Neoplasms                           43          41          28          36          27                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                 17          15          10          14           7                           
     Total Benign Neoplasms                            18          18          15          16           9                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms              23          22          12          16          16                           
     Total Malignant Neoplasms                         25          23          13          20          18                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              3           3           3           2                                       
     Total Metastatic Neoplasm                          6           4           7           7                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms               1           1           1                                                   
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   7                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
DISPOSITION SUMMARY                                                                                                                 
                                                                                                                                    
  Animals Initially in Study                          50           50           50           50           50                        
  Early Deaths                                                                                                                      
    Natural Death                                      6            3            4            9                                     
    Moribund Sacrifice                                                                        2            1                        
  Survivors                                                                                                                         
    Terminal Sacrifice                                43           45           46           39           49                        
    Natural Death                                      1            2                                                               
                                                                                                                                    
  Animals Examined Microscopically                    50           50           50           50           50                        
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ALIMENTARY SYSTEM                                                                                                                  
                                                                                                                                    
   Intestine Large, Colon                             (50)         (50)         (50)         (50)         (50)                      
   Intestine Large, Cecum                             (50)         (50)         (50)         (50)         (50)                      
   Intestine Small, Duodenum                          (50)         (50)         (50)         (50)         (49)                      
      Polyp Adenomatous                                             1 (2%)       1 (2%)                                             
   Intestine Small, Jejunum                           (50)         (50)         (50)         (50)         (50)                      
      Carcinoma                                        1 (2%)                                                                       
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Liver                                              (50)         (50)         (50)         (50)         (50)                      
      Hemangiosarcoma                                                                         1 (2%)                                
      Hepatocellular Carcinoma                         6 (12%)      7 (14%)      7 (14%)      4 (8%)       3 (6%)                   
      Hepatocellular Adenoma                           5 (10%)      7 (14%)      5 (10%)      5 (10%)      4 (8%)                   
      Hepatocellular Adenoma, Multiple                              2 (4%)                                                          
      Histiocytic Sarcoma                                                        1 (2%)       2 (4%)                                
   Mesentery                                          (2)                                    (1)                                    
      Squamous Cell Carcinoma, Metastatic, Stomach,                                                                                 
           Forestomach                                                                        1 (100%)                              
   Oral Mucosa                                                     (1)                                                              
      Pharyngeal, Squamous Cell Papilloma                           1 (100%)                                                        
   Pancreas                                           (50)         (50)         (50)         (50)         (50)                      
      Hemangioma                                                    1 (2%)                                                          
   Salivary Glands                                    (50)         (50)         (50)         (49)         (50)                      
   Stomach, Forestomach                               (48)         (50)         (50)         (48)         (50)                      
      Squamous Cell Carcinoma                                                                 1 (2%)                                
      Squamous Cell Papilloma                                                                 1 (2%)       1 (2%)                   
   Stomach, Glandular                                 (50)         (50)         (50)         (50)         (50)                      
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   8                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 CARDIOVASCULAR SYSTEM                                                                                                              
                                                                                                                                    
   Heart                                              (50)         (50)         (50)         (50)         (50)                      
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                                               1 (2%)                                
      Histiocytic Sarcoma                                                                     1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 ENDOCRINE SYSTEM                                                                                                                   
                                                                                                                                    
   Adrenal Cortex                                     (49)         (50)         (50)         (49)         (50)                      
      Subcapsular, Adenoma                             1 (2%)       1 (2%)       2 (4%)                    1 (2%)                   
   Pituitary Gland                                    (48)         (50)         (49)         (50)         (49)                      
      Pars Intermedia, Adenoma                         1 (2%)                                                                       
   Thyroid Gland                                      (50)         (49)         (50)         (50)         (50)                      
      Follicular Cell, Adenoma                                      1 (2%)       1 (2%)       1 (2%)                                
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENERAL BODY SYSTEM                                                                                                                
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 GENITAL SYSTEM                                                                                                                     
                                                                                                                                    
   Epididymis                                         (50)         (50)         (50)         (50)         (50)                      
      Hemangiosarcoma                                               1 (2%)                                                          
      Histiocytic Sarcoma                                                        1 (2%)       2 (4%)                                
   Preputial Gland                                    (50)         (50)         (50)         (50)         (50)                      
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Prostate                                           (50)         (50)         (50)         (50)         (50)                      
   Seminal Vesicle                                    (50)         (50)         (50)         (50)         (50)                      
   Testes                                             (50)         (50)         (50)         (50)         (50)                      
      Hemangiosarcoma                                               1 (2%)                                                          
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Interstitial Cell, Adenoma                       1 (2%)                    1 (2%)       1 (2%)       1 (2%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 HEMATOPOIETIC SYSTEM                                                                                                               
                                                                                                                                    
   Bone Marrow                                        (50)         (50)         (50)         (50)         (50)                      
      Histiocytic Sarcoma                                                        1 (2%)       1 (2%)                                
   Lymph Node                                         (3)          (2)          (2)          (3)          (2)                       
      Lumbar, Histiocytic Sarcoma                                                1 (50%)                                            
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page   9                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
HEMATOPOIETIC SYSTEM - cont                                                                                                         
      Mediastinal, Histiocytic Sarcoma                                           1 (50%)      1 (33%)                               
      Mediastinal, Squamous Cell Carcinoma,                                                                                         
          Metastatic, Stomach, Forestomach                                                    1 (33%)                               
      Renal, Fibrous Histiocytoma                                                1 (50%)                                            
      Renal, Histiocytic Sarcoma                                                 1 (50%)                                            
   Lymph Node, Mandibular                             (49)         (49)         (49)         (46)         (48)                      
      Histiocytic Sarcoma                                                        1 (2%)                                             
   Lymph Node, Mesenteric                             (48)         (49)         (46)         (46)         (50)                      
      Hepatocellular Carcinoma, Metastatic, Liver                   1 (2%)                                                          
      Histiocytic Sarcoma                                                        1 (2%)                                             
      Plasma Cell Tumor Malignant                                   1 (2%)                                                          
   Spleen                                             (50)         (50)         (50)         (49)         (50)                      
      Hemangiosarcoma                                  1 (2%)                    1 (2%)                                             
      Histiocytic Sarcoma                                                        1 (2%)       2 (4%)                                
   Thymus                                             (44)         (43)         (44)         (44)         (49)                      
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                     1 (2%)                                                          
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 INTEGUMENTARY SYSTEM                                                                                                               
                                                                                                                                    
   Skin                                               (50)         (50)         (50)         (50)         (50)                      
      Hemangiosarcoma                                                            1 (2%)                                             
      Histiocytic Sarcoma                                                                     1 (2%)                                
      Squamous Cell Papilloma                                       1 (2%)                                                          
      Subcutaneous Tissue, Hemangioma                  2 (4%)                                                                       
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 MUSCULOSKELETAL SYSTEM                                                                                                             
                                                                                                                                    
   Bone                                               (50)         (50)         (50)         (50)         (50)                      
      Rib, Fibrosarcoma                                                                                    1 (2%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 NERVOUS SYSTEM                                                                                                                     
                                                                                                                                    
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  10                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 RESPIRATORY SYSTEM                                                                                                                 
                                                                                                                                    
   Lung                                               (50)         (50)         (50)         (50)         (50)                      
      Alveolar/Bronchiolar Adenoma                     2 (4%)       6 (12%)      7 (14%)      1 (2%)       7 (14%)                  
      Alveolar/Bronchiolar Adenoma, Multiple           1 (2%)                                 1 (2%)                                
      Alveolar/Bronchiolar Carcinoma                   2 (4%)       5 (10%)      1 (2%)       2 (4%)       6 (12%)                  
      Carcinoma, Metastatic, Harderian Gland                                     1 (2%)                                             
      Hepatocellular Carcinoma, Metastatic, Liver      1 (2%)                    3 (6%)       2 (4%)                                
      Histiocytic Sarcoma                                                        1 (2%)       1 (2%)                                
   Nose                                               (48)         (48)         (48)         (48)         (50)                      
      Histiocytic Sarcoma                                                                     1 (2%)                                
   Pleura                                                          (1)                                    (1)                       
      Alveolar/Bronchiolar Carcinoma, Metastatic,                                                                                   
           Lung                                                     1 (100%)                                                        
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SPECIAL SENSES SYSTEM                                                                                                              
                                                                                                                                    
   Harderian Gland                                    (4)          (4)          (4)          (1)          (3)                       
      Adenoma                                          4 (100%)     4 (100%)     3 (75%)      1 (100%)     2 (67%)                  
      Carcinoma                                                                  1 (25%)                                            
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 URINARY SYSTEM                                                                                                                     
                                                                                                                                    
   Kidney                                             (50)         (50)         (50)         (50)         (50)                      
      Histiocytic Sarcoma                                                        1 (2%)       1 (2%)                                
   Urinary Bladder                                    (50)         (50)         (50)         (50)         (50)                      
      Squamous Cell Carcinoma, Metastatic, Stomach,                                                                                 
           Forestomach                                                                        1 (2%)                                
                                                                                                                                    
____________________________________________________________________________________________________________________________________
                                                                                                                                    
 SYSTEMIC LESIONS                                                                                                                   
                                                                                                                                    
   Multiple Organs                                   *(50)        *(50)        *(50)        *(50)        *(50)                      
      Histiocytic Sarcoma                                                        1 (2%)       2 (4%)                                
      Lymphoma Malignant                               4 (8%)       4 (8%)       1 (2%)       2 (4%)       2 (4%)                   
____________________________________________________________________________________________________________________________________
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
     *   Number of animals with any tissue examined microscopically                                                                 
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  11                                                               
                                                                                                                                   
NTP Experiment-Test: 56111-04  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                                        TRANS-CINNAMALDEHYDE                                   Date: 06/14/01  
Route: DOSED FEED                                                                                                 Time: 09:19:23  
____________________________________________________________________________________________________________________________________
                                                                                                                                    
         B6C3F1 MICE MALE                          UNTREATD     VEHICLE      .312%        .625%        1.25%                        
                                                   CONTROL      CONTROL                                                             
____________________________________________________________________________________________________________________________________
                                                                                                                                    
TUMOR SUMMARY                                                                                                                       
                                                                                                                                    
   Total Animals with Primary Neoplasms (b)            23          34          27          17          22                           
     Total Primary Neoplasms                           31          44          34          23          28                           
                                                                                                                                    
   Total Animals with Benign Neoplasms                 14          23          16           9          15                           
     Total Benign Neoplasms                            17          25          20          11          16                           
                                                                                                                                    
   Total Animals with Malignant Neoplasms              12          16          14          11          12                           
     Total Malignant Neoplasms                         14          19          14          12          12                           
                                                                                                                                    
   Total Animals with Metastatic Neoplasms              1           1           4           4                                       
     Total Metastatic Neoplasm                          1           3           4           6                                       
                                                                                                                                    
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
                                                                                                                                    
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
                                                                                                                                    
                                                                                                                                    
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                                                                                                    
                                                             Page  12                                                               
                                                                                                                                   
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------